Copart outlines 15M+ U.S. noninsurance auction TAM as international units rise 5.9% (NASDAQ:CPRT)
Earnings Call Insights: Copart, Inc. (CPRT) Q3 fiscal 2026 Management View “For the third quarter 2026, our global insurance unit ...
Monday, September 21, 2026
Tag: outlines
Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS (NASDAQ:ALXO)
Earnings Call Insights: ALX Oncology (ALXO) Q1 2026 Management view Seeking Alpha's Disclaimer: This article was automatically generated by an ...
TOMI outlines May 30, 2026 timing for Carbonium Core deal with $120M implied valuation (NASDAQ:TOMZ)
Earnings Call Insights: TOMI Environmental Solutions (TOMZ) Q1 2026 Management view "Q1 2026 marked a healthy start to the year" ...
Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex while targeting 6 data readouts before year-end (NASDAQ:KRYS)
Earnings Call Insights: Krystal Biotech (KRYS) Q1 2026 Management View "We delivered another quarter of global revenue growth with net ...
Great Southern outlines IT projects adding $200k-$250k a month over next 3-6 quarters (NASDAQ:GSBC)
Follow us on Google for the latest stock newsFollow Seeking Alpha on Google for the latest stock newsEarnings Call Insights: ...
Traws outlines $60M financing while targeting flu challenge study this summer and runway into Q1 2027 (NASDAQ:TRAW)
Follow us on Google for the latest stock newsFollow Seeking Alpha on Google for the latest stock newsEarnings Call Insights: ...
Frp holdings outlines 2026 NOI of $37.1M-$37.7M while integrating Altman platform (NASDAQ:FRPH)
Earnings Call Insights: FRP Holdings, Inc. (FRPH) Q4 2025 Management view “2025 was a transition year operationally... As we enter ...
Origin Materials outlines breakeven delay to 2028 and intensifies strategic review amid extended customer adoption timelines (NASDAQ:ORGN)
Follow us on Google for the latest stock newsFollow Seeking Alpha on Google for the latest stock newsEarnings Call Insights: ...
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit (NASDAQ:BCDA)
Earnings Call Insights: BioCardia (BCDA) Q4 2025 Management View Peter Altman, CEO, highlighted that BioCardia now has complete and final ...
Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline (NASDAQ:ARWR)
Earnings Call Insights: Arrowhead Pharmaceuticals (ARWR) Q1 2026 Management View Dr. Christopher Anzalone, Chairman, CEO & President, stated, "We had ...
Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.